Elutia
Elutia's revenue fell 15.0% to $12 million in fiscal 2025. Its operating margin was −218.9%, down from −212.3% a year earlier. Free cash flow was −$47 million. The diluted share count rose 58.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Elutia does
Elutia makes biologic matrices: thin sheets of processed human or animal tissue that surgeons use to repair and support soft tissue. It sells SimpliDerm, made from donated human skin and used mainly in breast reconstruction after cancer surgery, and patches made from pig intestine tissue, called ProxiCor, Tyke and VasCure, used to repair the heart and blood vessels. It sells them to US hospitals and other healthcare facilities through independent sales agents, and relies on single suppliers for each product line.
The company reports two segments, Women's Health (SimpliDerm) and Cardiovascular. Total sales fell to $12.3 million in 2025, mostly because of lower SimpliDerm sales. It names AbbVie's AlloDerm and Strattice, Stryker's DermACELL and Integra's SurgiMend among the products SimpliDerm competes with, and Gore and Terumo among the makers of patches that compete with its heart products.
In October 2025 Elutia sold its business of envelopes that hold heart devices such as pacemakers, EluPro and CanGaroo, to Boston Scientific for up to $88.0 million in cash. It now focuses on developing NXT-41, a new tissue matrix, and a version of it that slowly releases antibiotics at the surgical site to help prevent infection; both need FDA clearance before they can be sold. It is based in Gaithersburg, Maryland, and had 26 employees at the end of 2025.
Its biggest risks, as it describes them
- It faces lawsuits over recalls of two bone graft products it used to sell, and has no more insurance for one of them.
- Its new products need FDA clearance, which may be slow or may not come at all.
- It may need to raise more money, which may not be available on acceptable terms.
- Surgeons and hospitals may not adopt its products, especially where insurers do not pay for procedures that use them.
- Competition from larger companies with longer histories, more established products and more resources.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 30 | 17 | 19 | 13 | 36 |
| Debt incl. finance leases | 26 | — | 24 | 24 | — |
| Net debt (negative means net cash) | −4 | — | 4 | 11 | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 2.0x | — | — | — | — |
| Interest coverage | −4.3x | −6.9x | −5.3x | −6.4x | −3.6x |
| Current ratio | 1.8x | 1.2x | 0.7x | 0.7x | 2.2x |
| Quick ratio | 1.5x | 1.1x | 0.6x | 0.6x | 2.1x |
Cash flow
Projections
Project Elutia's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 7 insiders bought $215,115 of Elutia shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 30, 2026 | Kevin RakinDirector, 10% owner | Bought | 70,000 | $1.06 | $74,200 | Form 4 |
| Jan 30, 2026 | Guido J NeelsDirector | Bought | 20,000 | $1.04 | $20,800 | Form 4 |
| Jan 29, 2026 | Guido J NeelsDirector | Bought | 15,000 | $1.06 | $15,900 | Form 4 |
| Jan 28, 2026 | Guido J NeelsDirector | Bought | 15,000 | $1.06 | $15,900 | Form 4 |
| Dec 17, 2025 | Matthew FergusonChief Financial Officer | Bought | 60,000 | $0.53 | $31,800 | Form 4 |
| Dec 17, 2025 | HighCape Partners GP II LLC10% owner | Bought | 50,000 | $0.52 | $26,000 | Form 4 |
| Dec 17, 2025 | Brigid MakesDirector | Bought | 25,000 | $0.52 | $13,000 | Form 4 |
| Dec 17, 2025 | David ColpmanDirector | Bought | 12,500 | $0.51 | $6,375 | Form 4 |
| Dec 17, 2025 | Mills C RandalPresident and CEO, Director | Bought | 3,000 | $0.51 | $1,530 | Form 4 |
| Dec 2, 2025 | Matthew FergusonChief Financial Officer | Bought | 5,500 | $0.67 | $3,685 | Form 4 |
| Dec 1, 2025 | Matthew FergusonChief Financial Officer | Bought | 4,500 | $0.65 | $2,925 | Form 4 |
| Nov 24, 2025 | Mills C RandalPresident and CEO, Director | Bought | 5,000 | $0.60 | $3,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 2 of 9 | — |
| Rule of 40 | −85.6% | −202.7% | −394.8% |
| Altman Z'' | −20.18 | −29.13 | −8.05 |
| Accruals ratio | −28.3% | −78.7% | 199.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | Fail | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | 2 of 9 | — |
Compare
Put Elutia side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Elutia | FY25 | −15.0% | −218.9% | −379.8% | — | — | — | |
| Nano-X Imaging | FY25 | 15.4% | −600.8% | −345.6% | — | — | — | Compare |
| Nexgel | FY25 | 31.5% | −29.4% | −12.1% | — | — | — | Compare |
| CapsoVision | FY25 | 15.3% | −188.2% | −169.3% | — | — | — | Compare |
| Hyperfine | FY25 | 5.2% | −273.4% | −214.8% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 43 | 43 | 47 | 24 | 25 | 14 | 12 |
| Revenue growth | — | −0.5% | 11.0% | −49.7% | 3.8% | −41.5% | −15.0% |
| Gross profit | 20 | 21 | 19 | 12 | 11 | 7 | 7 |
| Research and development | 2 | 6 | 9 | 8 | 4 | 3 | 4 |
| Operating income | −8 | −14 | −23 | −35 | −30 | −31 | −27 |
| Net income | −12 | −22 | −25 | −33 | −38 | −54 | 53 |
| Diluted EPS (US$) | −18.48 | −8.88 | −2.38 | −2.38 | −2.07 | −1.86 | 0.87 |
| Diluted shares (millions) | 1 | 3 | 10 | 14 | 18 | 29 | 46 |
| Cash flow | |||||||
| Cash from operations | −7 | −14 | −15 | −21 | −22 | −23 | −45 |
| Capital expenditure | 1 | 1 | 0 | 0 | 0 | 1 | 2 |
| Free cash flow | −8 | −14 | −16 | −22 | −22 | −23 | −47 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 4 | 4 | 2 | 8 | 5 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 2 | 39 | 30 | 17 | 19 | 13 | 36 |
| Debt incl. finance leases | 21 | 30 | 26 | — | 24 | 24 | — |
| Total assets | 45 | 83 | 67 | 69 | 43 | 36 | 62 |
| Total liabilities | 55 | 62 | 54 | 74 | 82 | 82 | 35 |
| Shareholders' equity | −55 | 21 | 14 | −5 | −39 | −46 | 28 |
| Margins and ratios | |||||||
| Gross margin | 46.1% | 48.2% | 40.1% | 48.8% | 44.7% | 46.4% | 53.7% |
| Operating margin | −19.6% | −31.9% | −48.6% | −147.6% | −123.4% | −212.3% | −218.9% |
| Net margin | −27.8% | −51.1% | −52.4% | −137.9% | −152.2% | −372.9% | 434.2% |
| Free cash flow margin | −18.2% | −33.4% | −33.4% | −92.1% | −89.3% | −161.1% | −379.8% |
| Rule of 40 (growth + FCF margin) | — | −33.9% | −22.3% | −141.8% | −85.6% | −202.7% | −394.8% |
| Return on capital | — | — | −167.2% | — | — | — | — |
| Return on equity | — | — | −144.6% | −775.1% | — | — | — |
| Return on assets | — | −34.2% | −33.1% | −48.4% | −67.1% | −135.6% | 108.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — |